Does State Medicaid Cover Generic Tadalafil?

Why Coverage Varies So Much Across State Medicaid Programs

Each state administers its own Medicaid program under broad federal guidelines, which means formulary decisions about generic tadalafil are made independently by 50 different pharmacy and therapeutics committees. The Medicaid Drug Rebate Program requires states to cover nearly all FDA-approved drugs from manufacturers that participate in the rebate agreement, but federal law since the Deficit Reduction Act of 2005 allows states to impose prior authorization, quantity limits, and preferred-drug requirements [1]. For ED medications specifically, many states exercised an optional exclusion permitted under the Omnibus Budget Reconciliation Act provision that lets Medicaid programs exclude drugs used for erectile dysfunction [2].

The practical result: a 55-year-old man with BPH and ED in New York may receive tadalafil 5 mg daily with a $1 copay, while the same patient in Texas may face a prior authorization wall for any PDE5 inhibitor prescribed for ED. State managed-care organizations (MCOs) add another layer of variability because each MCO can maintain its own formulary within the state's minimum coverage floor [3].

Generic tadalafil entered the U.S. market in September 2018 after Cialis lost patent exclusivity, dropping per-tablet costs by over 90% according to FDA generic drug competition data. That price drop prompted several states to move generic tadalafil onto preferred tiers where brand Cialis had previously been excluded [4].

Tadalafil for BPH: The Easier Coverage Path

Tadalafil 5 mg once daily is FDA-approved for BPH signs and symptoms, both alone and in combination with the alpha-blocker tamsulosin. The LVHP trial (N=1,058) showed tadalafil 5 mg improved International Prostate Symptom Score (IPSS) by 4.9 points versus 2.3 for placebo at 12 weeks [5]. Because BPH is a non-controversial urological indication with no exclusion carve-out, most state Medicaid formularies list tadalafil 5 mg daily under their urology or genitourinary preferred drug class.

A 2021 review of publicly available state preferred drug lists found that 42 of 50 states and the District of Columbia included generic tadalafil 5 mg for BPH without prior authorization [6]. The remaining states required documentation of a trial of an alpha-blocker (tamsulosin or alfuzosin) or a 5-alpha reductase inhibitor (finasteride or dutasteride) before approving tadalafil, a step-therapy sequence aligned with the AUA BPH guideline recommendations [7].

For patients who have both BPH and ED, the 5 mg daily dose effectively treats both conditions simultaneously. The Brock et al. integrated analysis across five randomized trials (N=1,112) confirmed tadalafil improved erectile function across all severity subgroups, and subsequent labeling extended the daily-dose indication to BPH [8]. Clinicians can code the prescription under ICD-10 N40.1 (BPH with lower urinary tract symptoms) to align with the BPH indication, which typically faces fewer formulary barriers.

Tadalafil for ED: Restrictions, Exclusions, and Workarounds

Coverage for the ED indication is more complicated. Federal Medicaid policy allows, but does not require, states to exclude ED drugs. As of early 2026, approximately 20 states explicitly exclude PDE5 inhibitors for ED from their fee-for-service formulary, though several of those states permit coverage through managed-care carve-ins [9]. States that do cover tadalafil for ED almost universally impose quantity limits, typically 6 to 8 tablets per 30-day period for the 10 mg or 20 mg on-demand strengths.

Prior authorization criteria for ED coverage commonly require:

• A documented diagnosis of erectile dysfunction (ICD-10 N52.x)
• Age 18 or older
• Failure of, contraindication to, or intolerance of sildenafil (step therapy)
• No concurrent nitrate therapy, per FDA prescribing information safety warnings [10]
• No concurrent use of recreational drugs containing nitrates

The Hatzimouratidis et al. EAU guideline review confirmed that PDE5 inhibitors as a class are first-line pharmacotherapy for ED, with response rates of 65% to 80% across randomized trials [11]. Tadalafil's distinguishing characteristic is its 17.5-hour half-life, roughly four times longer than sildenafil's, which allows the daily low-dose regimen and a wider window of efficacy for on-demand use [12].

Some states have moved toward more permissive coverage. California's Medi-Cal added generic tadalafil to its preferred drug list for ED in 2023 with a 6-tablet-per-month limit and no step-therapy requirement. New York Medicaid covers up to 8 tablets monthly with prior authorization confirming the ED diagnosis. Illinois requires one prior PDE5 inhibitor trial [13].

Step Therapy Requirements State by State

Step therapy (also called "fail-first") requires patients to try a cheaper or preferred drug before the plan will authorize tadalafil. For Medicaid programs that cover ED drugs, the most common step-therapy sequence mandates a trial of generic sildenafil first. Sildenafil is often on the lowest generic tier with a $0 to $1.00 copay in Medicaid plans, making it the default first-line option for cost reasons rather than clinical superiority [14].

The Tsertsvadze et al. Cochrane-style systematic review of head-to-head PDE5 inhibitor comparisons found no significant difference in overall efficacy between sildenafil and tadalafil, though patient preference data consistently favored tadalafil's longer duration of action [15]. A randomized crossover trial by Eardley et al. (N=215) showed 73% of patients preferred tadalafil over sildenafil when given the choice, primarily because of the extended 36-hour window [16].

To satisfy step therapy, document at least a 4-week trial of sildenafil at an adequate dose (50 mg or 100 mg) on at least 4 to 6 occasions with insufficient response. Specific language matters: "patient tried sildenafil 100 mg on six separate occasions with <50% improvement in erection quality" is stronger than a vague note saying the drug "didn't work."

For the BPH indication, step therapy more commonly requires documentation that an alpha-blocker was tried for at least 4 weeks, per the AUA/SUFU guideline on lower urinary tract symptoms [7].

How to Read Your State's Formulary for Tadalafil

Every state Medicaid program publishes a preferred drug list (PDL), sometimes called a formulary, that categorizes covered medications by tier. Generic tadalafil typically falls into one of these tiers:

Tier 1 (preferred generic): lowest copay, usually $0 to $1.00. This is the most favorable placement and is common for the 5 mg BPH strength.

Tier 2 (non-preferred generic): copay of $1.00 to $3.90 depending on the state. Some states place on-demand strengths (10 mg, 20 mg) on this tier.

Non-formulary or excluded: not covered without an exception or appeal. This status is more common for the ED indication in restrictive states.

To find your state's current PDL, search "[state name] Medicaid preferred drug list" or visit Medicaid.gov's state plan page. Each MCO within your state may have a slightly different formulary. The CMS Medicaid managed care enrollment report estimates that over 72% of Medicaid beneficiaries are enrolled in managed care, making it essential to check your specific plan's drug list rather than relying solely on the state fee-for-service PDL [17].

Look for quantity limits noted alongside the listing. Common notations include "QL" (quantity limit), "PA" (prior authorization), and "ST" (step therapy). A listing that reads "tadalafil 5 mg, QL 30/30 days" means 30 tablets per month are covered, consistent with daily dosing for BPH.

Filing a Prior Authorization for Tadalafil on Medicaid

When prior authorization is required, the prescribing clinician (not the patient) submits a PA request to the state Medicaid program or MCO. Turnaround time for a standard PA is 24 to 72 hours in most states. Urgent PAs, defined as situations where delay could seriously jeopardize the patient's health, must be resolved within 24 hours under federal Medicaid regulations at 42 CFR § 438.210 [18].

A complete PA submission for tadalafil typically includes:

• Diagnosis and ICD-10 code (N52.01 for ED due to arterial insufficiency, N40.1 for BPH with LUTS)
• Clinical rationale, including relevant lab values (testosterone level if hypogonadism is a concomitant factor)
• Step-therapy documentation if applicable (dates, doses, and outcomes of prior sildenafil trial)
• Confirmation that no contraindicated concurrent medications are prescribed

The AUA erectile dysfunction guideline recommends PDE5 inhibitors as first-line ED pharmacotherapy, which provides clinical support for the PA narrative [19]. If the patient has comorbid BPH, emphasizing the dual indication of tadalafil 5 mg daily strengthens the request because it consolidates two drug classes (PDE5 inhibitor plus alpha-blocker alternative) into one medication.

How to Appeal a Medicaid Denial for Tadalafil

A denied PA triggers appeal rights under federal Medicaid law. Every state must provide a fair-hearing process, and MCOs must offer an internal grievance and appeal procedure before the state-level hearing [20]. Timelines vary, but the typical structure is:

Internal MCO appeal: must be filed within 60 days of the denial notice. The MCO has 30 days to respond (or 72 hours for expedited appeals). A peer-to-peer review between the prescribing clinician and the MCO's medical director can sometimes resolve the issue before a formal decision.

State fair hearing: if the MCO upholds the denial, the patient can request a state fair hearing, usually within 90 to 120 days of the MCO's final decision. The hearing is conducted by an administrative law judge. Patients may represent themselves or use a legal aid representative.

To strengthen the appeal, include a letter of medical necessity referencing clinical guidelines. Citing the Porst et al. meta-analysis (N=2,102 across 4 trials), which showed tadalafil 20 mg improved IIEF-EF domain scores by 7.0 to 9.4 points versus 0.6 to 1.6 for placebo, provides concrete efficacy data to counter a denial based on "medical necessity not established" [21].

For BPH-related denials, cite the Roehrborn et al. key trial (N=1,058) demonstrating statistically significant IPSS improvement with tadalafil 5 mg daily versus placebo (P<0.001) [5]. Include the patient's baseline IPSS score and any imaging showing prostate enlargement to support clinical need.

Cash-Pay and Discount Alternatives When Medicaid Denies Coverage

If coverage is denied and the appeal is unsuccessful, generic tadalafil remains one of the more affordable ED/BPH medications at cash-pay prices. The average retail price for 30 tablets of tadalafil 5 mg is approximately $25 to $45, and 10 tablets of tadalafil 20 mg cost roughly $15 to $30 depending on the pharmacy [22]. These prices are a fraction of the brand Cialis list price of roughly $450 per month.

Manufacturer savings cards (also called copay cards) are generally not usable with Medicaid. The OIG guidance on federal anti-kickback statute prohibits copay assistance for federally funded programs, including Medicaid, Medicare Part D, and TRICARE [23]. Patients on Medicaid who attempt to use a manufacturer coupon at the pharmacy will typically be rejected at the point of sale.

Alternatives for Medicaid patients facing a coverage gap:

• Patient assistance programs operated by generic manufacturers (income-based, application required)
• 340B-eligible pharmacies at federally qualified health centers, which can dispense at deeply discounted rates per HRSA 340B program rules [24]
• Pharmacy discount programs (GoodRx, RxSaver) for cash-pay pricing, which can sometimes undercut Medicaid copays for inexpensive generics

Tadalafil Dosing and Safety Considerations Relevant to Medicaid PA

Medicaid reviewers evaluate PA requests partly based on whether the requested dose aligns with FDA-approved labeling. The approved doses are:

• BPH or BPH+ED: 5 mg once daily
• ED (on-demand): 10 mg taken before anticipated sexual activity, adjustable to 20 mg or down to 5 mg based on efficacy and tolerability
• ED (daily): 2.5 mg once daily, adjustable to 5 mg

For patients on CYP3A4 inhibitors such as ketoconazole or ritonavir, the maximum recommended dose is 10 mg every 72 hours per the drug interaction section of the FDA label [10]. Renal impairment (CrCl 30 to 50 mL/min) does not require dose adjustment for the 5 mg daily regimen, though the on-demand starting dose should be reduced to 5 mg with a maximum of 10 mg no more frequently than every 48 hours [10].

Common adverse effects documented in the Brock et al. pooled safety analysis include headache (15%), dyspepsia (10%), back pain (6%), and nasal congestion (5%) [8]. The back pain and myalgia profile is more characteristic of tadalafil than sildenafil and typically resolves within 48 hours of onset.

Absolute contraindications relevant to PA review: concurrent nitrate use in any form, concurrent guanylate cyclase stimulator (riociguat) therapy, and known hypersensitivity to tadalafil [10]. PA reviewers will cross-reference the patient's medication list against these contraindications during clinical review.

Prescribers submitting Medicaid PAs should document baseline IIEF-5 scores for ED or IPSS scores for BPH, as these validated instruments provide measurable outcomes that PA reviewers and appeal judges can evaluate objectively.